Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and …
BACKGROUND The current TNM staging system for patients with hepatocellular carcinoma
(HCC) does not include liver function parameters and does not provide a precise prognosis …
(HCC) does not include liver function parameters and does not provide a precise prognosis …
Uniportal and single-incision video-assisted thoracic surgery: the state of the art
…, RHL Wong, RWH Lau, SCH Yu… - … and thoracic surgery, 2014 - academic.oup.com
Over the past decade, uniportal video-assisted thoracic surgery (VATS) has evolved
dramatically into a sophisticated technique capable of performing some of the most complex …
dramatically into a sophisticated technique capable of performing some of the most complex …
A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular …
Background: Single-agent doxorubicin has been widely used to treat unresectable
hepatocellular carcinoma (HCC), but the response rate is low (<20%) and there is no convincing …
hepatocellular carcinoma (HCC), but the response rate is low (<20%) and there is no convincing …
A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study
…, MMH Teng, I Szikora, A Berlis, J Reul, SCH Yu… - Stroke, 2007 - Am Heart Assoc
Background and Purpose— The purpose of this study was to assess the safety and
performance of the Wingspan stent system and Gateway percutaneous transluminal angioplasty …
performance of the Wingspan stent system and Gateway percutaneous transluminal angioplasty …
Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals
…, NBY Tsui, NYL Lam, RWK Chiu, SCH Yu… - Clinical …, 2002 - academic.oup.com
Background: As RNA is labile, we investigated whether circulating RNA in human plasma
may be present in a particle-associated form. Methods: Blood was collected from 27 healthy …
may be present in a particle-associated form. Methods: Blood was collected from 27 healthy …
[HTML][HTML] Federated deep learning for detecting COVID-19 lung abnormalities in CT: a privacy-preserving multinational validation study
Data privacy mechanisms are essential for rapidly scaling medical training databases to
capture the heterogeneity of patient data distributions toward robust and generalizable machine …
capture the heterogeneity of patient data distributions toward robust and generalizable machine …
[PDF][PDF] Treatment of pyogenic liver abscess: prospective randomized comparison of catheter drainage and needle aspiration
This study aims to compare the therapeutic effectiveness of continuous catheter drainage
versus intermittent needle aspiration in the percutaneous treatment of pyogenic liver abscesses…
versus intermittent needle aspiration in the percutaneous treatment of pyogenic liver abscesses…
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
TWT Leung, YZ Patt, W Lau, SKW Ho, SCH Yu… - Clinical Cancer …, 1999 - AACR
The purpose of this Phase II study was to determine the response rate, the toxicity, and the
effect on survival of the combination of cisplatin, doxorubicin, 5-fluorouracil, and α-IFN (PIAF) …
effect on survival of the combination of cisplatin, doxorubicin, 5-fluorouracil, and α-IFN (PIAF) …
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic …
…, EP Hui, HC Jeung, JK Roh, SCH Yu… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Epigenetic aberrations have been reported in hepatocellular carcinoma (HCC). In
this study of patients with unresectable HCC and chronic liver disease, epigenetic therapy …
this study of patients with unresectable HCC and chronic liver disease, epigenetic therapy …
[HTML][HTML] Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)-a correlative study to explore potential biomarkers for …
Background The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC. Data on
the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant chronic liver …
the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant chronic liver …